PI3K | 陶素生化

PI3K

T0579	Myricetin	Myricetin is a naturally-occurring flavonoid found in many grapes, berries, fruits, vegetables, herbs, as well as other plants. Walnuts are a rich dietary source. It has been shown
T1056	Isoprenaline hydrochloride	Isoproterenol is a potent beta-adrenergic agonist with the peripheral vasodilator, bronchodilator, and cardiac stimulating properties.
T1826	Voxtalisib Analogue	Voxtalisib (SAR245409, XL765)Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ ,also inhibits DNA-PK and mTOR.
T1827	Buparlisib	Buparlisib is an orally bioavailable specific oral inhibitor of the pan-class I PI3K (IC50s: 52/166/116/nM for p110α, p110β, and p110δ).
T1838	INK 128	INK 128 is an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
T1859	AZD8055	AZD8055 is an ATP-competitive mTOR inhibitor (IC50: 0.8 nM in MDA-MB-468 cells). It is ~1,000-fold selective for mTOR over all PI3K isoforms.
T1861	Omipalisib	GSK2126458 is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity.
T1879	3-Methyladenine	3-Methyladenine (3-MA) is a selective PI3KV inhibitor, and the IC50s against ps34 and PI3Kγ were 25/60 μM in HeLa cells, respectively.
T1894	Idelalisib	Idelalisib is a small molecule inhibitor of the PI3K catalytic subunit p110δ (IC50: 2.5 nM). The selectivity for p110δ is 40- to 300-fold than p110α/β/γ.
T1916	Apitolisib	Apitolisib, an effective, class I PI3K inhibitor for PI3Kα（IC50=5 nM）, PI3Kβ（IC50=27 nM）, PI3Kδ（IC50=7 nM）, PI3Kγ （IC50=14 nM）, is used in trials study of solid
T1921	Alpelisib	Alpelisib is an orally bioavailable PI3Kα inhibitor (IC50: 5 nM in a cell-free assay) with potential antineoplastic activity and minimal effect on PI3Kβ/γ/δ.
T1949	CZC24832	CZC24832 is a selective inhibitor of PI 3-kinase γ.
T1961	Vistusertib	AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.
T1970	Gedatolisib	Gedatolisib is a highly effective dual inhibitor targeting the PI3Kα/γ (IC50: 0.4/5.4 nM)and mTOR (IC50: 1.6 nM) in the PI3K/mTOR signaling pathway.
T1988	Duvelisib	Duvelisib is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunom
T1994	Pictilisib	Pictilisib (GDC-0941) is a potent pan inhibitor of class I catalytic subunits of PI3K (IC50s: 3/33/3/75 nM for p110α/β/δ/γ).
T1999	Taselisib	Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity.
T2008	LY294002	LY294002 is an inhibitor of PI3K (IC50s: 0.5/0.57/0.97 μM for PI3Kα/δ/β in cell-free assays). It also blocks autophagosome formation.
T2061	APY0201	APY0201 is a effective, highly specific, ATP-competitive PIKfyve inhibitor (IC50: 5.2 nM). It can interrupt the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(
T2073	GSK2636771	GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neopl
T2083	PI3065	PI-3065 is a novel potent and selective PI3K p110δ inhibitor.
T2084	ETP46464	ETP-46464 is an effective and specific ATR inhibitor (IC50: 25 nM).
T2174	Quercetin	Quercetin, a natural flavonoid present in vegetables, fruit, and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor.
T2235	Dactolisib	Dactolisib is an orally bioavailable inhibitor of PI3K and mTOR (IC50s: 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR).
T2248	AS605240	AS-605240 is an effective and specific inhibitor of PI3Kγ (IC50/Ki: 87.8 nM).
T2256	CNX1351	CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.
T2287	PIK-75 hydrochloride	PIK-75 Hydrochloride is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC
T2297	PIK294	PIK-294 is a excellently specific p110δ inhibitor(IC50=10 nM).
T2308	HS173	HS-173 is an effective PI3Kα inhibitor (IC50: 0.8 nM).
T2357	GSK1059615	GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.
T2365	Pilaralisib	Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treat
T2377	XL147 analogue	XL147 analogue is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ.
T2414	Torkinib	Torkinib (PP 242) is a selective and ATP-competitive mTOR inhibitor (IC50: 8 nM). It also inhibits mTORC1/2 (IC50s: 30/58 nM).
T2418	A66	A66 is a specific and effective p110α inhibitor(IC50=32 nM).
T2433	NU7026	NU7026 is an effective DNA-PK inhibitor (IC50: 0.23 μM, in cell-free assays), 60-fold selective for DNA-PK than PI3K and no inhibition against both ATM and ATR.
T2461	PIK90	PIK-90, a DNA-PK and PI3K inhibitor, suppresses p110α( IC50=11 nM), p110γ(IC50=18 nM) and DNA-PK(IC50=13 nM) .
T2616	PIK93	PIK-93 is the first potent, synthetic PI4K inhibitor with IC50 of 19 nM; inhibits PI3Kα with IC50 of 39 nM.
T2619	CH5132799	CH5132799 has been used in trials studying the treatment of Solid Tumors.
T2660	IC87114	IC-87114 is a specific PI3Kδ inhibitor(IC50=0.5 μM).
T2661	TGX221	TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.
T2667	PIK75	PIK-75, a DNA-PK and PI3K inhibitor, suppresses DNA-PK(IC50=2 nM), p110α(IC50=5.8 nM) and p110γ(IC50=76 nM).
T2672	TG100-115	TG100-115 is a PI3Kγ/δ inhibitor (IC50: 83/235 nM), with fewer effects on PI3Kα/β.
T2682	Acalisib	Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ.
T2685	KU55933	KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor.
T3153	Serabelisib	MLN1117 (INK1117) is a p110α/β/γ/δ inhibitor (IC50: 15/4.5/1.9/13.39μM).
T3190	PIK-inhibitors	PIK-inhibitors is a pan PI3K inhibitors,an analog of PI-103.
T3348	PIK293	PIK-293 is a PI3K inhibitor, for PI3Kδ( IC50=0.24 μM), and less potent for PI3Kα/β/ γ.
T3351	CC223	CC-223 is an orally available mTOR inhibitor with potential antitumor activity. CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and
T3410	Momordin Ic	Momordin Ic might represent a potential anticancer activity, by inducing apoptosis through oxidative stress-regulated mitochondrial dysfunction involving the MAPK and PI3K-mediated
T3541	CC115	CC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM).
T3556	NIH12848	NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
T3692	GNE 477	GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor.
T3705	GDC0084	GDC-0084 (RG7666) is a PI3K inhibitor with potential antineoplastic activity. GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, th
T3985	GDC0326	GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).
T3986	SF2523	SF2523 is a highly selective and potent inhibitor.
T4199	Desmethyl-VS-5584	Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
T4219	Autophinib	Autophinib is a potent autophagy inhibitor with a novel chemotype with IC50 values of 90 and 40 nM for autophagy in starvation induced autophagy assay and rapamycin induced autopha
T4220	BQR695	BQR-695 is a phosphatidylinositol 4-kinase (PI4K) inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
T4296	MTX211	MTX-211, an inhibitor of EGFR and PI3K, is used for the therapy of cancer and other diseases.
T6030	XL388	XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.
T6045	Torin 1	Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold selectivity for mTOR than PI3K.
T6072	BGT226	BGT226 (NVP-BGT226) is a class I PI3K/mTOR inhibitor for PI3Kα/β/γ (IC50: 4/63/38 nM) .
T6087	AZD6482	AZD 6482 is a potent and selective p110β inhibitor with IC50 of 0.69 nM and a PI3Kβ inhibitor with IC50 of 10 nM.
T6103	VS5584	VS-5584 is a pan-PI3K/mTOR kinase inhibitor.
T6110	YM201636	YM201636 (IC50=33 nM), a specific PIKfyve inhibitor, is less effective to p110α and insensitive to Fabl, which is yeast orthologue.
T6143	PI103	PI-103 is a potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50s: 2/3/3/15/30/23 nM for p110α/β/δ/γ, mTOR, and DNA-PK).
T6168	ZSTK474	PI3K Inhibitor ZSTK474 is an orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
T6208	AS252424	AS-252424 is a potent and selective inhibitor of PI3Kγ with IC50 of 33 nM; >10 fold selectivity for PI3Kγ versus PI3Kα.
T6251	PF04691502	PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity.
T6319	OSI027	OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ
T6322	Copanlisib	Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may resul
T6394	AS604850	AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.
T6433	CAY10505	CAY10505, a form of dehydroxyl of AS-252424, is a PI3Kγ inhibitor (IC50: 33 nM).
T6510	GDC0349	GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.
T6557	KU0060648	KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
T6704	TG100713	TG100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively.
T6731	WYE354	WYE-354(IC50=5 nM) is an effective, selective and ATP-competitive mTOR inhibitor. It blocks mTORC2/P-AKT(S473) and mTORC1/P-S6K(T389), not P-AKT(T308). The selectivity for mTOR is
T6732	WYE687	WYE-687 is an ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM; blocks mTORC1/pS6K(T389) and mTORC2/P-AKT(S473) but no effect observed on P-AKT(T308). Selectivity
T6757	AMG319	AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
T6773	AZD8186	AZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).
T6774	AZD8835	AZD8835 is a mixed inhibitor of PI3Kα/δ (IC50: 6.2/5.7 nM), also with selectivity against PI3Kβ/γ (IC50: 431/90 nM).
T6817	Deguelin	Deguelin is a PI3K/AKT Inhibitor, which is a natural product isolated from plants in the Mundulea sericea family.
T6845	GNE317	GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
T6883	LY3023414	LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, CO
T6938	PF4989216	PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively.
T6945	PIK-III	PIK-III, a selective inhibitor of VPS34 enzymatic activity, inhibits autophagy and results in the stabilization of autophagy substrates.
T7014	Voxtalisib	Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
T7015	VPS34-IN1	Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.
T2P2919	(4S)-4-Hydroxy-L-isoleucine	4-Hydroxyisoleucine (HIL) from fenugreek (Trigonella foenum-graecum) seeds is a potential insulinotropic (anti-diabetic) and anti-obesity amino acid. HIL stimulates glucose-depende
T5S0896	Loureirin A	Loureirin A has an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling.Loureirin A negatively affects agonist-induced platelet aggregation
T4976	TGR1202	TGR-1202 is a PI3Kδ inhibitor.
T4958	Alkannin	Shikonin is a natural red naphthoquinone pigment, has antimicrobial, anti-tumor, and anti-inflammatory effects; a purified shikonin preparation is widely used for the production of
T6283	Wortmannin	Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-P
T5166	Leniolisib	Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor (IC50: 11 nM).
T5432	IPI-549	IPI-549 is an inhibitor of PI3Kγ (IC50 = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively)
T5736	CYNARIN	CYNARIN is a natural product. It shows antioxidant and choleretic properties and is a potential immunosuppressive agent.
T5831	Selective PI3Kδ Inhibitor 1	Selective PI3Kδ Inhibitor 1 is a PI3Kδ Inhibitor(IC50 = 0.9 nM).
T6330	PI3Kδ-IN-2	PI3Kδ-IN-2 is a potent and selective inhibitor of PI3Kδ
T6799	IITZ-01	IITZ-01 is potent autophagy inhibitor with single-agent anticancer activity ( IC50 of 2.62 μM for PI3Kγ.)
T7166	GNE-493	GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3
T7343	PF-04979064	PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).
TQ0003	740 Y-P	740 Y-P is a potent and cell-permeable activator of PI3K.
TQ0009	UCB9608	UCB9608 is a selective and orally active PI4KIIIβ inhibitor (IC50: 11 nM), selective over PI3KC2 α, β, and γ lipid kinases.
TQ0044	Seletalisib	Seletalisib (UCB5857) is a potent and specific PI3Kδ inhibitor (IC50: 12 nM).
TQ0229	ETP-46321	ETP-46321 is an effective and orally bioavailable PI3Kα/PI3Kδ inhibitor (Ki: 2.3/14.2 nM).
TQ0313	NVP-BAG956	NVP-BAG956 is an ATP-competitive PI3K inhibitor (IC50s: 34/56/112/444 nM for PI3Kδ/PI3Kα/PI3Kγ/PI3Kβ).
T2265	PI3K-IN-2	PI3K-IN-2 is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta
T2018	Apilimod	Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
T4398	LX2343	LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates aut
T7879	TASP0415914	TASP0415914 is an orally potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ). T
T7944	VPS34 inhibitor 1 (Compound 19, PIK-III analogue)	VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is a potent and selective inhibitor of VPS34( IC50 : 15 nM)
TN1461	Butin	Butin has antioxidant activity, can protect cells against H2O2-induced apoptosis, oxidative DNA damage and oxidative mitochondrial dysfunction; it attenuates oxidative stress by ac
TN1711	Gossypetin	Gossypetin has anti-mutagenic, anti-atherosclerotic, antioxidant, as well as cytoprotective and antimicrobial effects, it inhibits bone resorption through down-regulating lysosomal
TN1805	Isosilybin B	Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activity that is mediated
TN1819	Kaempferol 3-neohesperidoside	Kaempferol 3-neohesperidoside has insulin-like properties in terms of glucose lowering, it stimulates glucose uptake in the rat soleus muscle via the PI3K and PKC pathways and, at
TN2019	Orobol	Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover, it has sensitization effect, it can produce produced cisplatin (DDP) sensitivity in hu
TN2244	Sulfuretin	Sulfuretin is a potent anti-oxidant, has protective effect against t-BHP-induced oxidative damage in human liver-derived HepG2 cells is attributable to its ability to scavenge ROS
TN2328	Zeylenone	Zeylenone has good antitumor efficacy, it inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. Zeylenone shows inhibito
TN1376	alpha-Solanine	Alpha-Solanine alters antioxidative enzyme activities and MDA and PCO concentrations and GST activity in fat body and midgut.
TN1594	DL-Syringaresinol	(+)-Syringaresinol shows inhibitory activity of Helicobacter pylori motility with the IC50 value is 50 microg/ml.
TN2259	Taurocholic acid	Taurocholic acid feeding shows cytoprotective effects on the biliary tree after adrenergic denervation of the liver; taurocholic acid feeding prevents tumor necrosis factor-alpha-i
TN1033	Sennidin A	Sennidin A, has two hydroxyanthraquinone-like moieties, exerts inhibition on NS3 helicase with IC50 values of 0.8 μM.
TN1034	Sennidin B	Sennidin B stimulates glucose incorporation in rat adipocytes.
TN1153	Polyporenic acid C	Polyporenic acid C shows inhibitory activity against human collagenase.
TN1347	8-Prenylkaempferol	8-Prenylkaempferol is an effective agent for attenuating pro-inflammatory NO induction, it may be an anti-inflammatory agent for suppressing influenza A virus-induced RANTES produc
TN1367	Alismol	Alismol has antihypertensive action, it decreases cardiac output, heart rate and left ventricular pressure, but it increases coronary flow, it has been used for the prevention of a
TN1459	Bufarenogin	Bufarenogin has inhibitory activity on human kidney Na(+)/K(+)-ATPase, it has cytotoxicity against HepG2 and MCF-7 human cancer cells.
TN1504	Citreorosein	Citreorosein is a cAMP phosphodiesterase inhibitor, it has anti-inflammatory effect, inhibits proinflammatory cytokines production through the inhibition of both MAPKs and AKT-medi
T12115	MSC2360844	MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).
T12275	NVP-QAV-572	NVP-QAV-572 is a inhibitor of PI3K(IC50 of 10 nM).
T12310	ON 146040	ON 146040 is a potent inhibitor of PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) .
T12365	PARP/PI3K-IN-1	PARP/PI3K-IN-1 is a potent inhibitor of PARP/PI3K(pIC50 values of 8.22).
T12367	Parsaclisib	Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP)
T12455	PI3K/HDAC-IN-1	PI3K/HDAC-IN-1 is a potent PI3K and HDAC dual inhibitor(IC50s of 8.1 nM and 1.4 nM, respectively).
T12456	PI3K-IN-10	PI3K-IN-10 is a potent inhibitor of pan-PI3K .
T12457	PI3K-IN-6	PI3K-IN-6 is an oral active and highly selective inhibitor of phosphoinositide 3-kinase (PI3K) β/δ(IC50 values of 7.8 nM/5.3 nM , respectively).
T12458	PI3K-IN-9	PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ(IC50 of 8.9 nM).
T12459	PI3K/mTOR Inhibitor-2	PI3K/mTOR Inhibitor-2 is a potent dual inhibitor of pan-PI3K/mTOR(PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 3.4/34/16/1/4.7 nM).
T12460	PI3K/mTOR Inhibitor-1	PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)
T12461	PI3Kdelta inhibitor 1	PI3Kdelta inhibitor 1 is a potent, selective and orally available inhibitor of PI3Kδ with an IC50 of 1.3 nM.
T12462	PI3Kδ-IN-1	PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM).
T12463	PI3kδ inhibitor 1	PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).
T12464	PI3Kγ inhibitor 1	PI3Kγ inhibitor 1 is a inhibitor of PI3Kδ and PI3Kγ.
T12465	PI3Kγ inhibitor 2	PI3Kγ inhibitor 2 is an orally bioavailable inhibitor of PI3Kγ(Ki of 4 nM).
T12466	AZD3458	AZD3458 is a potent and remarkably selective inhibitor of PI3Kγ (PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ with pIC50s of 9.1, 5.1, <4.5, and 6.5 , respectively).
T12467	PI4KIII beta inhibitor 3	PI4KIII beta inhibitor 3 is a novel and high effective inhibitor of PI4KIIIβ (IC50 of 5.7 nM).
T12468	PI4KIIIbeta-IN-10	PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ (IC50 of 3.6 nM).
T12469	PI4KIIIbeta-IN-9	PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ(IC50 of 7 nM). .
T14214	AMG 511	AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 exhibits anti-tumor
T14511	BAY1082439	BAY1082439 is a selective and orally bioavailable inhibitor of PI3Kα/β/δ, and also inhibits mutated forms of PIK3CA, with highly effective in inhibiting Pten-null prostate cance
T14552	Dactolisib Tosylate	Dactolisib Tosylate (BEZ235 Tosylate) is an inhibitor of dual PI3K and mTOR kinase(IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively). Dactolisib Tosylate also inh
T12589	PI3Kα/mTOR-IN-1	PI3Kα/mTOR-IN-1 is a potent dual inhibitor PI3Kα/mTOR(an IC50 of 7 nM for PI3Kα in a cell assay, and Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respec
T14944	CGS 15943	CGS 15943 is an orally bioavailable non-xanthine antagonist of Adenosine Receptor. In transfected CHO cells, its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2
T14998	Copanlisib dihydrochloride	Copanlisib dihydrochloride is an ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ, and PI3Kγ) with antitumor activit
T15375	GDC-0077	GDC-0077 is an orally available and selective inhibitor of PI3Kα (IC50: 0.038 nM). GDC-0077 is more selective for mutant versus wild-type PI3Kα. It exerts its activity by bindi
T15420	GS-9901	GS-9901 is a highly selective and orally active inhibitor of PI3Kδ (IC50: 1 nM). It also has the potential to treat rheumatoid arthritis.
T13119	Tenalisib	Tenalisib (RP6530) is a potent and selective inhibitor of PI3Kδ and PI3Kγ(IC50 values of 25 and 33 nM, respectively.)
T13140	Umbralisib R-enantiomer	Umbralisib R-enantiomer (TGR-1202 R-enantiomer) is an inhibitor of PI3Kδ, which is the less active enantiomer of TGR-1202.
T11129	Duvelisib R enantiomer	Duvelisib R enantiomer is an enantiomer with low activity of Duvelisib and is an inhibitor of PI3K.
T11381	Pictilisib dimethanesulfonate	Pictilisib dimethanesulfonate is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
T10660	CAL-130	CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
T10660L	CAL-130 Hydrochloride	CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
T10660L2	CAL-130 Racemate	CAL-130 Racemate is the racemate of CAL-130. CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
T11610	Idelalisib D5	Idelalisib is a highly selective and orally bioavailable p110δ inhibitor. Idelalisib D5 is a deuterium labeled Idelalisib.
T13311	Vps34-IN-2	Vps34-IN-2 is a potent and selective Vps34 inhibitor(IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively).
T10804	CHMFL-PI3KD-317	CHMFL-PI3KD-317 is a highly potent, selective, and orally active PI3Kδ inhibitor (IC50: 6 nM) with the antiproliferative effects on cancer cells. It inhibits PI3Kδ-mediated Akt T
T15431	Nemiralisib	Nemiralisib is a potent and highly selective inhibitor of PI3Kδ (pKi: 9.9).
T15592	IPI-3063	IPI-3063 is an effective and selective inhibitor of PI3K p110δ (IC50: 2.5 ± 1.2 nM).
T13973	(Z)-GW 5074	(Z)-GW 5074 interacts with both mHTT (mutant huntingtin protein) and LC3.
T13389	ZD-0892	ZD-0892 is a selective and poten neutrophil elastaset inhibitor(human neutrophil elastase and porcine pancreatic elastase with Kis of 6.7 and 200 nM, respectively).
T15800	LY117018	LY117018 shows antiproliferative effects on breast cancer cell lines. LY117018 is a Raloxifene analog and is a selective estrogen receptor modulator.
T16530	BF738735	BF738735 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 5.7 nM).
T11818	LAS191954	LAS191954 is a selective, potent and orally active PI3Kδ inhibitor for inflammatory diseases treatment(IC50 : 2.6 nM).
T16841	SAR-260301	SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).
T12831L	SAR405	SAR405 suppresses autophagy induced either by starvation or by mTOR inhibition. SAR405 is a first-in-class and ATP-competitive inhibitor of PI3K class III isoform Vps34 (IC50=1.2
T16908	Sonolisib	Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).
T17066	Umbralisib hydrochloride	Umbralisib hydrochloride is a novel PI3Kδ inhibitor (IC50 and EC50 of 22.2 nM and 24.3 nM, respectively). Umbralisib hydrochloride is also active against CK1ε (EC50: 6.0 μM).
T2S0501	Ilexgenin A	Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
T2S0606	Bakkenolide A	Bakkenolide A has antifeedant and growth inhibitory effects on neonate variegated cutworms, it inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
T2S0820	Karanjin	Karanjin is a potent Volume-regulated anion channels(VRACs) current inhibitor, the VRAC inhibition might be responsible for its anti-angiogenic effects. Karanjin possesses antioxid
T2S1040	Jolkinolide B	Jolkinolide B has potent anti-inflammatory, and antitumor activities, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulat
T2S1975	Ponicidin	Ponicidin has anti-leukemia, immunoregulatory and anti-inflammatory functions, it also has anti-viral function especially in the upper respiratory tract infection. Ponicidin has an
T3229	Cytochalasin D	Cytochalasin D is an actin inhibitor, the removal of actin stress fibers is crucial for the chondrogenic differentiation. It may be an inhibitor of some fertilization processes suc
TN3218	7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one	7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one as a beneficial compound to ameliorate the deleterious effects of Aβ on dendrite integrity and cell survival, and may provide new insig
TN3655	Cimiside E	Cimiside E has anti-inflammatory activity, it selectively inhibits TNF-α-induced expression of VCAM-1 at least by upregulation of PPAR-γ, and signals for ERK1/2, PI3K, and PKC ar
TN3691	Communic acid	Communic acid has antibacterial activity, including against mycobacterial. trans-Communic acid has potential to be utilized as anti-wrinkling agents and cosmetic ingredients, as th
TN3726	Cudraflavone B	Cudraflavone B has anti-proliferative activity, mouse brain monoamine oxidase (MAO) inhibitory effects, apoptotic actions in human gastric carcinoma cells and mouse melanoma cells,
TN3753	Dalbergioidin	Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. It shows a melanin biosynthesis inhibition zone in the culture plate of Streptomyces bikiniensis that h
TN3806	Dehydroglyasperin C	Dehydroglyasperin C is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C possesses potent antioxidant, cancer chemopreventive, and neur
TMA0291	Dehydroglyasperin D	Dehydroglyasperin D exhibits anticancer, anti-inflammatory, anti-obesity, antioxidant and anti-aldose reductase effects, it inhibits the proliferation of HT-29 human colorectal can
TMA2474	Delta-Tocotrienol	Delta-tocotrienol is a potential angiogenic inhibitor, it (2.5-5 microM) can significantly suppress human colorectal adenocarcinoma cells (DLD-1-CM) -induced tube formation, migrat
TN4046	Excisanin A	ExcisaninA may be a potent inhibitor of AKT signaling pathway in tumor cells, it can inhibit invasion by suppressing MMP-2 and MMP-9 expression, it may be a potential anti-metastat
TN4213	Hirsutenone	Hirsutenone has potent antioxidant activity, it shows significant free radical scavenging activity and exhibits inhibition effect on the mitochondrial lipid peroxidation.Hirsutenon
TN4263	Isoangustone A	Isoangustone A has antitumor activity, it can induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells, it inhibits cell proliferation by targeting PI3K,
TN4652	Niazimicin	Niazimicin are NF-B and PI3K inhibitors, which shows antimicrobial, hypotensive and spasmolytic activities. Niazimicin has potent antitumor promoting activity in the two-stage carc
TN5050	Sprengerinin C	Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can strongly suppress tum
TMA0507	Tomatidine	Tomatidine shows antibiotic, and anti-inflammatory activities, it significantly suppresses the activity of ACAT and leads to reduction of atherogenesis. Tomatidine inhibits the inv
TN5201	Uncarinic acid E	Uncarinic acid E has anti-cancer activity, it induces apoptosis in HepG2 cells via accumulation of p53, alters the Bax/Bcl-2 ratio, and activates caspases, resulting in cytochrome
T8651	Idelalisib	Idelalisib is a selective inhibitor of p110δ(IC50 : 2.5 nM; in cell-free assays); shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-
TQ0003L	740 Y-P(TFA)
TQ0003L	740 Y-P(TFA)